Design, Synthesis and in vitro Controlled Release of New Adamantanodiarylketone Antimycobacterials

Abstract

In the present investigation, the synthesis, the biology and the development of matrix tablet formulations for the in vitro controlled release of new adamantane diarylketone antimycobacterial derivatives, is presented. In the skeleton of the new compounds, a diarylketone, functionalized by a 2‐hydroxypropylenoxy‐3‐butylamine, a 2‐hydroxypropylenoxy‐3‐hexylamine and a 1‐(2‐hydroxyoctyl)piperidin‐4‐yl moiety, is incorporated at the C‐1 adamantane position. The new derivatives were tested against the H37Rv Mycobacterium tuberculosis strain and exhibited satisfactory activity. In view of their lipophilic character, it was intriguing to examine their in vitro dissolution profile in buffer solutions simulating the gastric and intestinal environments. To this end, matrix tablets of the most active compound, {4‐[(adamantan‐1‐yl)phenyl‐4‐(3‐(butylamino)‐2‐hydroxypropoxy)]phenyl}methanone (A), incorporating the appropriate excipients, were prepared using the direct compression method. The preliminary test results show that its dissolution profile is in alignment with the desired pattern for the per os administration of tuberculocidal agents.